Program
aflibercept
Also written as “Aflibercept”, “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)” and “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”.
Its studies are mostly in Macular Degeneration · Macular Edema · Colorectal Neoplasms · Lymphoma, Non-Hodgkin · Retinal Vein Occlusion, led by 15 companies.
Drug pageAflibercept: every studyMany companies study it; this page follows only the 86 they lead. All 268 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticalsits history only | 251 open or running | phase 4since Nov 2, 2012 | May 13, 2002 | none ahead |
| Bayerits history only | 230 open or running | phase 4since Apr 10, 2014 | Mar 12, 2008 | none ahead |
| Sanofiits history only | 200 open or running | phase 3since May 16, 2006 | Jan 30, 2006 | none ahead |
| Novartisits history only | 40 open or running | phase 4since Jul 22, 2016 | Jul 22, 2016 | none ahead |
| Amgenits history only | 31 open or running | phase 3since Feb 13, 2020 | Feb 13, 2020 | Jul 31, 2027phase 3 · NCT07614776 |
| Sam Chun Dang Pharm.its history only | 20 open or running | phase 3since Jul 17, 2020 | Jul 17, 2020 | none ahead |
| AbbVieits history only | 11 open or running | phase 2since Mar 16, 2022 | Mar 16, 2022 | Jun 2031phase 2 · NCT05296447 |
| AO GENERIUMits history only | 11 open or running | phase 3since Sep 18, 2026 | Sep 18, 2026 | May 2028phase 3 · NCT07844148 |
| bioeq-gmbhits history only | 10 open or running | phase 3since Aug 11, 2020 | Aug 11, 2020 | none ahead |
| cinnagenits history only | 10 open or running | phase 3since Sep 18, 2022 | Sep 18, 2022 | none ahead |
| Exegenesis Bioits history only | 11 open or running | phase 1since Jan 30, 2025 | Jan 30, 2025 | Feb 2029phase 1 · NCT06817343 |
| formycon-agits history only | 10 open or running | phase 4since Nov 25, 2024 | Nov 25, 2024 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Apr 19, 2022 | Apr 19, 2022 | none ahead |
| Samsung Bioepisits history only | 10 open or running | phase 2since Sep 21, 2026 | Sep 21, 2026 | none ahead |
| the-emmes-company-llcits history only | 10 open or running | phase 3since Oct 22, 2013 | Oct 22, 2013 | none ahead |
Also a collaborator on its studies: REGENXBIO and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 46 earlier studies, Jul 10, 2009 to Jul 22, 2022.
- Jul 21, 2022Named afliberceptINNProposed as its International Nonproprietary Name in WHO's List 127
- Aug 19, 2022Phase 4 study in Diabetic Macular EdemaBayer · NCT05511038 · 100 enrolled · India
- Sep 18, 2022cinnagen’s first study: phase 3 study in Macular DegenerationNew to cinnagencinnagen · NCT05587062 · 168 enrolled · Iran, Islamic Republic of
- Jan 20, 2023Phase 3 study in Chorioretinal Vascular DiseaseAmgen · NCT05704725 · 49 enrolled · United States
- Apr 28, 2023Phase 3 study in Macular Edema Secondary to Retinal Vein OcclusionBayer · NCT05850520 · 892 enrolled · United States, Australia, Austria and more
- Aug 3, 2023Phase 3 study in Diabetic Macular Edema (DME)Regeneron Pharmaceuticals · NCT05989126 · 35 enrolled · United States
- May 15, 2024Phase 3 study in Diabetic Macular EdemaBayer · NCT06422507 · 333 enrolled · China, Hong Kong
- Jul 1, 2024Phase 3 study in Neovascular Age-Related Macular DegenerationRegeneron Pharmaceuticals · NCT06491914 · 1,126 enrolled · United States, Puerto Rico
- Sep 8, 2024Phase 4 study in Diabetic Macular EdemaBayer · NCT06591598 · 51 enrolled · Czechia, Hungary, Slovakia
- Nov 25, 2024formycon-ag’s first study: phase 4 study in Macular DegenerationNew to formycon-agformycon-ag · NCT06708637 · 30 enrolled · United States
- Jan 30, 2025Exegenesis Bio’s first study: phase 1 study in Macular DegenerationNew to Exegenesis BioExegenesis Bio · NCT06817343 · 12 enrolled · United States
- Mar 24, 2026Phase 2 study in Macular DegenerationSam Chun Dang Pharm. · NCT07501052 · 33 enrolled · United States
- May 22, 2026Phase 3 study in Neovascular Age-related Macular DegenerationAmgen · NCT07614776 · 304 planned · United States, Czechia, Hungary and more
- Sep 18, 2026AO GENERIUM’s first study: phase 3 study in nAMDNew to AO GENERIUMAO GENERIUM · NCT07844148 · 180 planned · Russia
- Sep 21, 2026Samsung Bioepis’s first study: phase 2 study in Neovascular Age-related Macular DegenerationNew to Samsung BioepisSamsung Bioepis · NCT07844343 · 33 enrolled · South Korea
Ahead
- Jul 31, 2027Primary completion: phase 3 study in Neovascular Age-related Macular DegenerationAmgen · NCT07614776
- May 2028Primary completion: phase 3 study in nAMDAO GENERIUM · NCT07844148
- Feb 2029Primary completion: phase 1 study in Macular DegenerationExegenesis Bio · NCT06817343
- Jun 2031Primary completion: phase 2 study in Diabetic RetinopathyAbbVie · NCT05296447
TargetBeta
“Vascular endothelial growth factor A inhibitor; Placenta growth factor inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 86 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07844343Neovascular Age-related Macular Degeneration · South Korea | 2 | Completed | Samsung Bioepis | Sep 22, 2026 | 33 |
| NCT07844148nAMD · Russia | 3 | Recruiting | AO GENERIUM | May 2028 | 180 |
| NCT07614776Neovascular Age-related Macular Degeneration · United States, Czechia, Hungary and more | 3 | Recruiting | Amgen | Jul 31, 2027 | 304 |
| NCT07501052Macular Degeneration · United States | 2 | Completed | Sam Chun Dang Pharm. | May 27, 2026 | 33 |
| NCT06817343Macular Degeneration · United States | 1 | Active, not recruiting | Exegenesis Bio | Feb 2029 | 12 |
| NCT06708637Macular Degeneration · United States | 4 | Completed | formycon-ag | Oct 8, 2024 | 30 |
| NCT06591598Diabetic Macular Edema · Czechia, Hungary, Slovakia | 4 | Completed | Bayer | Oct 14, 2025 | 51 |
| NCT06491914Neovascular Age-Related Macular Degeneration · United States, Puerto Rico | 3 | Active, not recruiting | Regeneron Pharmaceuticals | Aug 26, 2025 | 1,126 |
| NCT06422507Diabetic Macular Edema · China, Hong Kong | 3 | Completed | Bayer | Dec 29, 2025 | 333 |
| NCT05989126Diabetic Macular Edema (DME) · United States | 3 | Completed | Regeneron Pharmaceuticals | May 31, 2024 | 35 |
| NCT05850520Macular Edema Secondary to Retinal Vein Occlusion · United States, Australia, Austria and more | 3 | Completed | Bayer | Nov 7, 2024 | 892 |
| NCT05704725Chorioretinal Vascular Disease · United States | 3 | Completed | Amgen | Feb 17, 2023 | 49 |
| NCT05587062Macular Degeneration · Iran, Islamic Republic of | 3 | Completed | cinnagen | Jul 31, 2022 | 168 |
| NCT05511038Diabetic Macular Edema · India | 4 | Completed | Bayer | Apr 16, 2024 | 100 |
| NCT05473715Macular Degeneration · Canada, United Kingdom | 4 | Terminated | Bayer | Jul 11, 2023 | 3 |
| NCT05345236Wet Age-related Macular Degeneration · China | 3 | Completed | Qilu Pharmaceutical | Jan 25, 2022 | 366 |
| NCT05296447Diabetic Retinopathy · United States | 2 | Active, not recruiting | AbbVie | Jun 2031 | 103 |
| NCT05282004Neovascular Age-related Macular Degeneration (nAMD) · United States | 3 | Completed | Novartis | Sep 7, 2022 | 36 |
| NCT05161806Neovascular Age-related Macular Degeneration (nAMD) · United States | 3 | Completed | Novartis | May 4, 2022 | 30 |
| NCT04864834Neovascular Age-related Macular Degeneration · United States, Australia, Austria and more | 3 | Completed | Novartis | Jul 7, 2022 | 485 |
| NCT04522167Neovascular Age-related Macular Degeneration · Bulgaria, Czechia, Hungary and more | 3 | Completed | bioeq-gmbh | Jun 23, 2022 | 434 |
| NCT04480463Macular Degeneration · United States, Australia, Bulgaria and more | 3 | Completed | Sam Chun Dang Pharm. | Sep 8, 2022 | 576 |
| NCT04429503Diabetes Mellitus, Type 1 · United States, Canada, Czechia and more | 3 | Completed | Regeneron Pharmaceuticals | May 30, 2022 | 660 |
| NCT04270747Macular Degeneration · United States, Canada, Czechia and more | 3 | Completed | Amgen | Jul 18, 2022 | 576 |
| NCT04126317Macular Degeneration · United States, Puerto Rico | 2 | Completed | Regeneron Pharmaceuticals | May 14, 2021 | 106 |
| NCT04101721Retinopathy of Prematurity · United States, Bulgaria, Colombia and more | 3 | Completed | Regeneron Pharmaceuticals | Aug 18, 2022 | 127 |
| NCT04015180Retinopathy of Prematurity · Argentina, Belgium, Brazil and more | 3 | Completed | Bayer | Sep 19, 2025 | 100 |
| NCT04004208Retinopathy of Prematurity · Argentina, Austria, Belgium and more | 3 | Completed | Bayer | Feb 12, 2021 | 113 |
| NCT03767738Chorioretinal Vascular Disease · United States | 4 | Completed | Regeneron Pharmaceuticals | Aug 19, 2020 | 65 |
| NCT03639675Glaucoma, Neovascular · Japan | 3 | Completed | Bayer | Feb 14, 2019 | 16 |
| NCT02878681Visual Impairment Due to Diabetic Macular Edema | 4 | Withdrawn | Novartis | Sep 2017 | 0 |
| NCT02818998Macular Edema · Austria, Canada, Czechia and more | 3 | Completed | Bayer | Nov 13, 2018 | 463 |
| NCT02800642Retinal Vein Occlusion · Australia, Canada, Denmark and more | 4 | Completed | Bayer | Jul 31, 2019 | 162 |
| NCT02718326Nonproliferative Diabetic Retinopathy · United States, Germany, Hungary and more | 3 | Completed | Regeneron Pharmaceuticals | Aug 6, 2018 | 402 |
| NCT02712008Diabetic Macular Edema · United States | 2 | Completed | Regeneron Pharmaceuticals | Jul 10, 2017 | 302 |
| NCT02581995Macular Edema · Austria, Canada, Czechia and more | 4 | Completed | Bayer | Aug 9, 2017 | 560 |
| NCT02581891Macular Degeneration · Australia, Canada, France and more | 4 | Completed | Bayer | Apr 26, 2019 | 287 |
| NCT02540954Macular Degeneration · Austria, Canada, Czechia and more | 3 | Completed | Bayer | Dec 24, 2019 | 336 |
| NCT02418754Neovascular Age-Related Macular Degeneration · United States, Japan | 2 | Terminated | Regeneron Pharmaceuticals | Aug 17, 2016 | 505 |
| NCT02396316Glaucoma, Neovascular · Japan | 3 | Completed | Bayer | Jun 16, 2016 | 54 |
| NCT02305238Wet Macular Degeneration · Japan | 4 | Completed | Bayer | Dec 22, 2016 | 288 |
| NCT02120950Neovascular Macular Degeneration · Australia, Germany, Hong Kong and more | 4 | Completed | Bayer | Aug 12, 2016 | 333 |
| NCT01969708Retinal Vein Occlusion · United States | 3 | Completed | the-emmes-company-llc | Nov 2016 | 362 |
| NCT01955629Colorectal Cancer Metastatic · Italy | 2 | Terminated | Sanofi | Mar 2015 | 4 |
| NCT01882868Colorectal Cancer Metastatic · Japan | 2 | Completed | Sanofi | Aug 2015 | 62 |
| NCT01783886Macular Edema · China, Hong Kong, Korea, Republic of and more | 3 | Completed | Bayer | Mar 2015 | 381 |
| NCT01722045Macular Degeneration · United States | 4 | Completed | Regeneron Pharmaceuticals | Sep 2015 | 154 |
| NCT01661270Colorectal Cancer Metastatic · China, Hong Kong, Japan and more | 3 | Completed | Sanofi | Oct 2014 | 332 |
| NCT01670721Colorectal Cancer Metastatic · France | 3 | Completed | Sanofi | Jun 2015 | 175 |
| NCT01571284Colorectal Cancer Metastatic · United States, Belgium, Brazil and more | 3 | Completed | Sanofi | Jan 31, 2017 | 781 |
| NCT01521559Retinal Vein Occlusion · United States, Canada, Japan | 3 | Completed | Regeneron Pharmaceuticals | Aug 2013 | 183 |
| NCT01512966Macular Edema · Japan | 3 | Completed | Bayer | Sep 2013 | 73 |
| NCT01482910Macular Degeneration · China | 3 | Completed | Bayer | Mar 2014 | 304 |
| NCT01363440Diabetic Retinopathy · United States | 3 | Completed | Regeneron Pharmaceuticals | Jan 2013 | 466 |
| NCT01331681Diabetes Mellitus · Australia, Austria, Czechia and more | 3 | Completed | Bayer | Jun 3, 2013 | 406 |
| NCT01249664Myopia, Degenerative · Hong Kong, Japan, Korea, Republic of and more | 3 | Completed | Bayer | Feb 2013 | 122 |
| NCT01148615Neoplasms · China | 1 | Completed | Sanofi | Sep 2011 | 20 |
| NCT01012973Retinal Vein Occlusion · Australia, Austria, France and more | 3 | Completed | Bayer | Feb 2011 | 177 |
| NCT00964795Macular Degeneration · United States, Canada | 3 | Completed | Regeneron Pharmaceuticals | Aug 2013 | 323 |
| NCT00943072Macular Edema · United States, Canada, Colombia and more | 3 | Completed | Regeneron Pharmaceuticals | Oct 2010 | 189 |
How it is read
Names in the registry
- “Aflibercept”, 9 entries
- “Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept injection (VEGF Trap-Eye, BAY86-5321)”, 8 entries
- “aflibercept”, 7 entries
- “Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)”, 7 entries
Codes read as this program: BAY865321, SCD411.
Conditions, from the studies’ own filings
- Macular Degeneration, 28 studies
- Macular Edema, 15 studies
- Colorectal Neoplasms, 8 studies
- Lymphoma, Non-Hodgkin, 5 studies
- Retinal Vein Occlusion, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.